Shopping Cart
Remove All
Your shopping cart is currently empty
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | 8-10 weeks | 8-10 weeks | |
| 5 mg | $483 | 8-10 weeks | 8-10 weeks | |
| 10 mg | $692 | 8-10 weeks | 8-10 weeks |
| Description | meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. |
| In vivo | Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients.?The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5];?p=0.014, HR=0.37, 95%CI[0.155-0.833]).?The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group.?No adverse effect was found in meplazumab-treated patients.?Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 2413715-21-4 |
| Relative Density. | no data available |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.